Imperial College London
Alternate

Emeritus ProfessorMustafaDjamgoz

Faculty of Natural Sciences, Department of Life Sciences

Emeritus Professor in Cancer Biology
 
 
 
//

Contact

 

+44 (0)20 7594 5370m.djamgoz

 
 
//

Location

 

Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lastraioli:2021:10.3390/cancers13153832,
author = {Lastraioli, E and Fraser, SP and Guzel, RM and Iorio, J and Bencini, L and Scarpi, E and Messerini, L and Villanacci, V and Cerino, G and Ghezzi, N and Perrone, G and Djamgoz, MBA and Arcangeli, A},
doi = {10.3390/cancers13153832},
journal = {Cancers},
pages = {1--14},
title = {Neonatal Nav1.5 protein expression in human colorectal cancer: immunohistochemical characterization and clinical evaluation},
url = {http://dx.doi.org/10.3390/cancers13153832},
volume = {13},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Voltage-gated Na+ channels (VGSCs) are expressed widely in human carcinomas and play a significant role in promoting cellular invasiveness and metastasis. However, human tissue-based studies and clinical characterization are lacking. In several carcinomas, including colorectal cancer (CRCa), the predominant VGSC is the neonatal splice variant of Nav1.5 (nNav1.5). The present study was designed to determine the expression patterns and clinical relevance of nNav1.5 protein in human CRCa tissues from patients with available clinicopathological history. The immunohistochemistry was made possible by the use of a polyclonal antibody (NESOpAb) specific for nNav1.5. The analysis showed that, compared with normal mucosa, nNav1.5 expression occurred in CRCa samples (i) at levels that were significantly higher and (ii) with a pattern that was more delineated (i.e., apical/basal or mixed). A surprisingly high level of nNav1.5 protein expression also occurred in adenomas, but this was mainly intracellular and diffuse. nNav1.5 showed a statistically significant association with TNM stage, highest expression being associated with TNM IV and metastatic status. Interestingly, nNav1.5 expression co-occurred with other biomarkers associated with metastasis, including hERG1, KCa3.1, VEGF-A, Glut1, and EGFR. Finally, univariate analysis showed that nNav1.5 expression had an impact on progression-free survival. We conclude (i) that nNav1.5 could represent a novel clinical biomarker (‘companion diagnostic’) useful to better stratify CRCa patients and (ii) that since nNav1.5 expression is functional, it could form the basis of anti-metastatic therapies including in combination with standard treatments.
AU  - Lastraioli,E
AU  - Fraser,SP
AU  - Guzel,RM
AU  - Iorio,J
AU  - Bencini,L
AU  - Scarpi,E
AU  - Messerini,L
AU  - Villanacci,V
AU  - Cerino,G
AU  - Ghezzi,N
AU  - Perrone,G
AU  - Djamgoz,MBA
AU  - Arcangeli,A
DO  - 10.3390/cancers13153832
EP  - 14
PY  - 2021///
SN  - 2072-6694
SP  - 1
TI  - Neonatal Nav1.5 protein expression in human colorectal cancer: immunohistochemical characterization and clinical evaluation
T2  - Cancers
UR  - http://dx.doi.org/10.3390/cancers13153832
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000681793300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.mdpi.com/2072-6694/13/15/3832
UR  - http://hdl.handle.net/10044/1/91182
VL  - 13
ER  -
Download